{"id":"W4401324671","doi":"10.3390/vaccines12080883","title":"Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study","year":2024,"lang":"en","type":"article","venue":"Vaccines","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Institute of Allergy and Infectious Diseases; AstraZeneca","keywords":"Immunogenicity; Medicine; Vaccination; Placebo; Neutralizing antibody; Internal medicine; Antibody; Antibody titer; Coronavirus disease 2019 (COVID-19); Randomized controlled trial; Immunology; Titer; Infectious disease (medical specialty); Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008436739,0.0008458545,0.001932562,0.0004290199,0.0009920936,0.001441981,0.0005052624,0.001348219,0.001843159],"category_scores_gemma":[0.004439785,0.0004252144,0.002215616,0.0004522253,0.0005642005,0.001369808,0.0007073979,0.002264004,0.0005940761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008249772,"about_ca_system_score_gemma":0.001060503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001025115,"about_ca_topic_score_gemma":0.0012462,"domain_scores_codex":[0.9980495,0.0006567598,0.0001589339,0.0002244022,0.0004382656,0.0004720745],"domain_scores_gemma":[0.9960151,0.000675321,0.001307973,0.0004782244,0.0007671285,0.0007561534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3095518,0.05187233,0.2704774,0.002009506,0.01029801,0.002073754,0.002165219,0.004114702,0.08442748,0.0004057907,0.01046769,0.2521363],"study_design_scores_gemma":[0.02235423,0.4122322,0.5372108,0.0001671925,0.003305062,0.001207042,0.0003610856,0.001467269,0.009736019,0.0004680531,0.01135401,0.00013707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896918,0.003337923,0.00130529,0.000318409,0.00007997861,0.001108304,0.002098063,0.00008460906,0.001975626],"genre_scores_gemma":[0.9904675,0.000779006,0.0006737952,0.0009897087,0.0001092684,0.0008846792,0.004574368,0.00002549532,0.001496304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008436739,"threshold_uncertainty_score":0.04461825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03817204875476456,"score_gpt":0.3710456522787309,"score_spread":0.3328736035239664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}